

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2013</b>		<b>June 30, 2013</b>	
	<b>International</b>	<b>Total</b>	<b>International</b>	<b>Total</b>
	<b>Net Sales</b>	<b>Net Sales</b>	<b>Net Sales</b>	<b>Net Sales</b>
<b>Net sales, as reported</b>	\$ 17,932	\$ 60,572	\$ 31,464	\$ 116,865
Currency impact as compared to prior period	267	267	447	447
<b>Net sales, excluding the impact of foreign currency</b>	<u>\$ 18,199</u>	<u>\$ 60,839</u>	<u>\$ 31,911</u>	<u>\$ 117,312</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2013	June 30, 2012 <sup>(1)</sup>	June 30, 2013	June 30, 2012 <sup>(1)</sup>
<b>Operating Income from Continued Operations</b>				
<b>Operating (loss) income, as reported</b>	\$ (13,181)	\$ (426)	\$ (26,407)	\$ 2,296
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	195	48	302	96
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	334	208	691	208
Transition costs - OrthoRecon divestiture	2,623	—	2,623	—
Due diligence, transaction and transition costs - BioMimetic <sup>(2)</sup>	1,446	—	8,943	—
Total	4,403	208	12,257	208
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	717	370	1,547	370
<i>Other Reconciling Items:</i>				
Restructuring charges	—	254	—	431
<b>Operating (loss) income, as adjusted</b>	<u>\$ (7,866)</u>	<u>\$ 454</u>	<u>\$ (12,301)</u>	<u>\$ 3,401</u>
<b>Operating (loss) income, as adjusted, as a percentage of net sales</b>	<u>(13.0)%</u>	<u>0.9%</u>	<u>(10.5)%</u>	<u>3.2%</u>

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating

adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) For the six months ended June 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense

related to the conversion of BioMimetic options to Wright Medical options.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2013	June 30, 2012 <sup>(1)</sup>	June 30, 2013	June 30, 2012 <sup>(1)</sup>
<b>Net Income</b>				
<b>Loss from continuing operations before taxes, as reported</b>	\$ (21,748)	\$ (1,992)	\$ (33,070)	\$ (1,064)
<i>Pre-tax impact of reconciling items:</i>				
Restructuring charges	—	254	—	431
Inventory step-up amortization	195	48	302	96
Distributor conversion and non-competes	1,051	578	2,238	578
Non-cash interest expense on 2017 Convertible Notes	2,152	—	4,269	—
Derivatives mark-to-market adjustment	(1,000)	—	1,000	—
Transition costs - OrthoRecon divestiture	2,623	—	2,623	—
Due diligence, transaction and transition costs - BioMimetic <sup>(2)</sup>	1,446	—	8,943	—
CVR mark-to-market adjustment	5,840	—	5,840	—
Gain on previously held investment in BioMimetic	—	—	(7,798)	—
<b>(Loss) income from continuing operations before taxes, as adjusted</b>	<u>(9,441)</u>	<u>(1,112)</u>	<u>(15,653)</u>	<u>41</u>
<b>Benefit for income taxes, as reported</b>	\$ (6,209)	\$ (625)	\$ (12,613)	\$ (121)
Restructuring charges	—	96	—	164
Inventory step-up amortization	76	18	118	37
Distributor conversion and non-competes	410	230	874	230
Non-cash interest expense on 2017 Convertible Notes	855	—	1,673	—
Derivatives mark-to-market adjustment	(378)	—	400	—
Transition costs - OrthoRecon divestiture	1,025	—	1,025	—
Due diligence, transaction and transition costs - BioMimetic	565	—	2,003	—
<b>(Benefit) provision for income taxes, as adjusted</b>	<u>\$ (3,656)</u>	<u>\$ (281)</u>	<u>\$ (6,520)</u>	<u>\$ 310</u>
<b>Effective tax rate, as adjusted</b>	<u>38.7%</u>	<u>25.2%</u>	<u>41.7%</u>	<u>775.0%</u>
<b>Net loss from continuing operations, as adjusted</b>	<u>\$ (5,785)</u>	<u>\$ (831)</u>	<u>\$ (9,133)</u>	<u>\$ (269)</u>
<b>Net (loss) income from discontinued operations, as reported</b>	\$ (1,792)	\$ 2,077	\$ 11,561	\$ 6,214
<b>Reconciling items related to discontinued operations, net of tax<sup>(3)</sup></b>	<u>\$ 2,393</u>	<u>\$ 1,759</u>	<u>\$ (8,534)</u>	<u>\$ 3,584</u>
<b>Net (loss) income, as adjusted</b>	<u><u>\$ (5,184)</u></u>	<u><u>\$ 3,005</u></u>	<u><u>\$ (6,106)</u></u>	<u><u>\$ 9,529</u></u>

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating

adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

(2) For the six months ended June 30, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense

related to the conversion of BioMimetic options to Wright Medical options.

(3) For the three month periods ended June 30, 2013 and 2012, amounts include the after tax impacts of \$0.7 million and \$2.1

million of U.S. governmental inquiries and DPA costs, \$0.4 million and \$0.2 million of amortization of distributor non-

competes, \$2.8 million and \$0 of transaction costs associated with the OrthoRecon divestiture, and \$0 and

\$0.5 million of restructuring charges, respectively. For the six month periods ended June 30, 2013 and 2012, amounts include \$1.8 million and \$4.9 million of U.S. governmental inquiries and DPA costs, \$0.8 million and \$0.2 million of amortization of distributor non-competes, \$2.8 million and \$0 of transaction costs associated with the OrthoRecon divestiture, a gain of \$19.4 million and \$0 for estimated product liability insurance recoveries, and \$0 and \$1.2 million of restructuring charges, respectively.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<b>Three Months Ended June 30, 2013</b>		<b>Three Months Ended June 30, 2012 <sup>(1)</sup></b>	
	<b>As Reported</b>	<b>As Adjusted</b>	<b>As Reported</b>	<b>As Adjusted</b>
<b>Basic net loss from continuing operations</b>	\$ (15,539)	\$ (5,785)	\$ (1,367)	\$ (831)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
<b>Diluted net loss from continuing operations</b>	\$ (15,539)	\$ (5,785)	\$ (1,367)	\$ (831)
Diluted net (loss) income from discontinued operations	(1,792)	601	2,077	3,836
<b>Diluted net (loss) income</b>	(17,331)	(5,184)	710	3,005
<b>Basic shares</b>	46,234	46,234	38,715	38,715
Dilutive effect of stock options and restricted shares	N/A	N/A	NA	N/A
Dilutive effect of convertible notes	N/A	N/A	N/A	N/A
<b>Diluted shares</b>	46,234	46,234	38,715	38,715
Net loss from continuing operations per share, diluted	\$ (0.34)	\$ (0.13)	\$ (0.04)	\$ (0.02)
Net (loss) income from discontinued operations per share, diluted	\$ (0.04)	\$ 0.01	\$ 0.05	\$ 0.10
Net (loss) income per share, diluted	\$ (0.37)	\$ (0.11)	\$ 0.02	\$ 0.08

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

	Six Months Ended June 30, 2013		Six Months Ended June 30, 2012 <sup>(1)</sup>	
	As Reported	As Adjusted	As Reported	As Adjusted
<b>Basic net loss from continuing operations</b>	\$ (20,457)	\$ (9,133)	\$ (943)	\$ (269)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
<b>Diluted net loss from continuing operations</b>	\$ (20,457)	\$ (9,133)	\$ (943)	\$ (269)
Diluted net income from discontinued operations	11,561	3,027	6,214	9,798
<b>Diluted net (loss) income</b>	(8,896)	(6,106)	5,271	9,529
<b>Basic shares</b>	43,849	43,849	38,604	38,604
Dilutive effect of stock options and restricted shares	N/A	N/A	NA	N/A
Dilutive effect of convertible notes	N/A	N/A	N/A	N/A
<b>Diluted shares</b>	43,849	43,849	38,604	38,604
Net loss from continuing operations per share, diluted	\$ (0.47)	\$ (0.21)	\$ (0.02)	\$ (0.01)
Net income from discontinued operations per share, diluted	\$ 0.26	\$ 0.07	\$ 0.16	\$ 0.25
Net (loss) income per share, diluted	\$ (0.20)	\$ (0.14)	\$ 0.14	\$ 0.25

(1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
**(continued)**

	Three Months Ended		Six Months Ended	
	June 30, 2013	June 30, 2012 <sup>(1)</sup>	June 30, 2013	June 30, 2012 <sup>(1)</sup>
<b>Net Income per Diluted Share</b>				
<b>Net loss from continuing operations, as reported, per diluted share</b>	\$ (0.34)	\$ (0.04)	\$ (0.47)	\$ (0.02)
Interest expense on convertible notes	N/A	N/A	N/A	N/A
Effect of convertible notes on diluted shares	N/A	N/A	N/A	N/A
Inventory step-up amortization	0.00	0.00	0.00	0.00
Distributor conversion and non-competes	0.01	0.01	0.03	0.01
Non-cash interest expense on 2017 Convertible Notes	0.03	—	0.06	—
Derivatives mark-to-market adjustment	(0.01)	—	0.01	—
CVR mark-to-market adjustment	0.13	—	0.14	—
Transition costs - OrthoRecon divestiture	0.03	—	0.04	—
Due diligence, transaction and transition costs - BioMimetic	0.02	—	0.17	—
Gain on previously held investment in BioMimetic	—	—	(0.19)	—
<b>Net loss from continuing operations, as adjusted, per diluted share <sup>(2)</sup></b>	\$ (0.13)	\$ (0.02)	\$ (0.21)	\$ (0.01)

- (1) Beginning in 2013, we do not adjust reported earnings for non-cash stock-based compensation expense in calculating adjusted earnings. 2012 adjusted earnings have been recast to reflect this change.
- (2) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

**Wright Medical Group, Inc.**  
**Reconciliation of Free Cash Flow**  
(dollars in thousands--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2013</b>	<b>June 30, 2012</b>	<b>June 30, 2013</b>	<b>June 30, 2012</b>
Net cash provided by operating activities	\$ 10,923	\$ 22,033	\$ 5,755	\$ 41,113
Capital expenditures	(5,995)	(4,042)	(9,735)	(8,573)
Free cash flow	\$ 4,928	\$ 17,991	\$ (3,980)	\$ 32,540